Continuous Renal Replacement Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Continuous Renal Replacement Therapy Market is expected to register a CAGR of 7.2% during the forecast period. Continuous renal replacement therapy (CRRT) is commonly used in critically ill patients with acute kidney injury, particularly patients who are hemodynamically unstable to provide renal support.

Acute kidney injury (AKI) is a sudden episode of kidney damage or kidney failure that happens within a few hours or a few days. Acute kidney injury (AKI) results in build-up of waste products in blood and makes it hard for kidneys to keep the right balance of fluid in the body. Acute kidney injury (AKI) can also affect other organs such as the brain, heart, and lungs. Acute kidney injury generally common in patients who are in the hospital, in intensive care units, and especially in older adults. According to the International Society of Nephrology, every year approximately 13.3 million cases of acute kidney injury (AKI) globally, particularly high in emerging countries, where annual incidence is estimated to be 11.3 million. Increasing geriatric population and incidences of acute kidney injury, technological advancements in continuous renal replacement therapy are the key driving factors in continuous renal replacement therapy market.

Key Market Trends

Continuous Venovenous Haemofiltration Segment is Expected to Hold a Major Market Share in the Continuous Renal Replacement Therapy Market

• Continuous Veno-Venous Hemofiltration (CVVH) is a temporary treatment for patients suffering with acute renal failure who are unable to tolerate hemodialysis and are unstable. With Continuous Veno-Venous Hemofiltration (CVVH), a dialysis catheter is placed in one of the main veins of the body.
• According to International Society of Nephrology, Acute kidney injury (AKI) is experienced by 13.3 million patients every year globally and between 5.3 and 10.5 million people require dialysis or transplantation.
• Continuous venovenous haemofiltration segment hold a significant market share in the continuous renal replacement therapy market and is anticipated to show similar trend over the forecast period due to high acceptance of continuous venovenous haemofiltration by nephrologists, because it is more feasible than the other modes and also incurs less complications than other modes of continuous renal replacement therapy.
• Increasing geriatric population and incidences of acute kidney injury and technological advancements are the key driving factors in the continuous venovenous haemofiltration segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the global continuous renal replacement therapy market due to rise in geriatric population and increasing incidences of acute kidney injury in this region. According to Centers for Disease Control and Prevention (CDC), approximately 30 million people or 15% of United States adults are estimated to have chronic kidney disease (CKD). chronic kidney disease (CKD) is estimated to be more common in women (16%) than in men (13%). Furthermore, high adoption rates of new technologies in continuous renal replacement therapy and the presence of well-established healthcare infrastructure is fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Continuous Renal Replacement Therapy Market is moderately fragmented competitive and consists of several major players. In terms of market share, few of the major manufacturers are currently dominating the capital equipment segment of the market. Some of the companies which are currently dominating the market are Asahi Kasei Medical Co., Ltd, B. Braun Melsungen AG, Baxter International, Inc, Fresenius Medical Care AG & Co. KgaA, Infomed SA, Medica SpA, Medical Components, Inc, Medites Pharma Spol. S.R.O, Medtronic PLC, and Toray Medical Co., Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support